<DOC>
	<DOCNO>NCT02398526</DOCNO>
	<brief_summary>This observational prospective single arm cohort study design assess pain bone pain related quality life metastatic Castration Resistant Prostate Cancer ( mCRPC ) patient receive Radium-223 real life nuclear medicine practice set . In addition , overall survival , time next tumor treatment ( TTNT ) , time first symptomatic skeletal event ( SSE ) , course blood count , safety assess .</brief_summary>
	<brief_title>Pain Evaluation Radium-223 Treated Castration Resistant Prostate Cancer Patients With Bone Metastases</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms , Castration-Resistant</mesh_term>
	<mesh_term>Succinylcholine</mesh_term>
	<mesh_term>Radium Ra 223 dichloride</mesh_term>
	<criteria>Adult male patient diagnose CRPC symptomatic bone metastasis without know visceral metastasis Decision initiate treatment Radium223 make per investigator 's routine treatment practice Patients participate investigational program intervention outside routine clinical practice participate another observational study Xofigo</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Observational study</keyword>
	<keyword>Bone metastasis</keyword>
	<keyword>Hormone Refractory Prostatic Cancer</keyword>
	<keyword>Xofigo</keyword>
	<keyword>Radium-223</keyword>
</DOC>